한글목차

본 보고서는 전 세계 위식도 접합부 선암 임상시험을 조사 분석하여 각국의 임상시험 수와 평균 등록자 수 데이터, 임상시험 중인 주요 약물 정보 등의 정보를 제공합니다.

목차

표 리스트

도표 리스트

• 보고서 가이던스
• GlobalData 임상시험 보고서 범위
• 임상시험 : 지역별
• 임상시험과 평균 등록수 : 국가별
• 아시아태평양의 임상시험에 기여하고 있는 주요 5개국
• 유럽의 임상시험에 기여하고 있는 주요 5개국
• 북미의 임상시험에 기여하고 있는 주요 국가
• 중동 및 아프리카의 임상시험에 기여하고 있는 주요 5개국
• 중남미 임상시험에 기여하고 있는 주요 5개국
• G7 국가의 임상시험 : 종양 임상시험에 전체 대비 위식도 접합부 선암 임상시험 비율
• G7 국가의 임상시험 : 단계별
• G7 국가의 임상시험 : 시험 현황별
• E7 국가의 임상시험 : 종양 임상시험에 전체 대비 위식도 하는 위식도 접합부 선암 비율
• E7 국가의 임상시험 : 단계별
• E7 국가의 임상시험 : 시험 현황별
• 임상시험 : 단계별
• 진행중인 시험 : 단계별
• 임상시험 : 시험 현황별
• 임상시험 : 엔드포인트 현황별
• 일정기간에 걸쳐 채택된 피험자
• 임상시험 : 스폰서 유형별
• 저명한 스폰서
• 위식도 접합부 선암 치료 임상시험에 참가하고 있는 주요 기업
• 저명한 약제
• 위식도 접합부 선암에 관한 최신 임상시험 뉴스
• 2025년 11월 25일 : Imfinzi, 미국에서 조기 위암과 식도 위암 환자에 대한 처음이자 유일한 주술기 면역치료로서 승인
• 2025년 11월 7일 : Marengo, SITC 2025에서 PD-1 내성 암을 대상으로 한 2상 임상시험 인비카푸스 알파 단독요법의 하이라이트 구두 발표
• 2025년 10월 30일 : Foghorn Therapeutics, 선택적 ARID1B 프로그램 업데이트를 발표
• 2025년 10월 28일 : Alphamab Oncology, 이중 표적 HER2 표적 ADC JSKN003가 PROC 치료제로서 FDA 조기 일괄 승인 수속 지정을 받았다고 발표
• 2025년 10월 22일 : I-Mab, 2025년 10월 23일에 개최되는 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference에서 Givastomig 단독요법 최신 데이터를 발표
• 2025년 10월 20일 : Bemarituzumab 제일 선택약이, FGFR2b를 과잉 발현하는 위암 또는 위식도 접합부 선암 단기 생존률을 개량
• 2025년 10월 20일 : Sichuan Kelun-Biotech Biopharmaceutical, 2025 European Society for Medical Oncology(ESMO) Congress에서의 SKB-315에 관한 프레젠테이션을 발표
• 2025년 10월 20일 : Boan Biotech가 ESMO 2025에서 BA1301 초기 연구 결과를 발표
• 2025년 10월 17일 : Imfinzi를 기반으로 한 레지멘이 MATTERHORN 2상 임상시험에서 화학요법 단독과 비교해 조기 위암 사망 리스크를 22% 저감
• 2025년 10월 17일 : HER2 양성 상부 소화관 암에 대한 신규 표적치료 결과는 가지각색
• 2025년 10월 14일 : I-Mab, 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference에서 Givastomig 단독요법 최신 데이터에 대해 간략하게 발표
• 2025년 10월 3일 : ALX Oncology, 40th SITC Annual Meeting에서 위암 예측 바이오마커로서의 CD47 발현에 초점을 맞춘 2상 임상시험 데이터를 발표
• 임상시험 개요 현황
• 약어
• 정의
• 조사 방법
• 2차 조사
• GlobalData에 대해
• 문의
• 면책사항
• 정보원

영문목차

GlobalData's clinical trial report, "Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025" provides an overview of Gastroesophageal (GE) Junction Carcinomas Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

• Report Guidance
• GlobalData Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Gastroesophageal (GE) Junction Carcinomas
• Nov 25, 2025: Imfinzi Approved in the US as First and Only Perioperative Immunotherapy for Patients With Early Gastric and Gastroesophageal Cancers
• Nov 07, 2025: Marengo Presents Oral Presentation Highlights Single-Agent of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
• Oct 30, 2025: Foghorn Therapeutics Announces Updates for Selective ARID1B Program
• Oct 28, 2025: Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC
• Oct 22, 2025: I-Mab To Present Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
• Oct 20, 2025: First-line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b
• Oct 20, 2025: Sichuan Kelun-Biotech Biopharmaceutical Announced Presentation On SKB-315 at the 2025
• European Society for Medical Oncology (ESMO) Congress
• Oct 20, 2025: Boan Biotech Presents Early Findings about BA1301 at ESMO 2025
• Oct 17, 2025: IMFINZI-Based Regimen Reduced the Risk of Death by 22% in Early Gastric Cancer vs. Chemotherapy Alone in MATTERHORN Phase III Trial
• Oct 17, 2025: Mixed Outcomes With Novel Targeted Therapies for HER2-Positive Upper GI Cancers
• Oct 14, 2025: I-Mab To Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
• Oct 03, 2025: ALX Oncology to Present Data from Phase 2 Trial, Highlighting CD47 Expression as a Predictive Biomarker in Gastric Cancer, at 40th SITC Annual Meeting
• Clinical Trial Profile Snapshots
• Abbreviations
• Definitions
• Research Methodology
• Secondary Research
• About GlobalData
• Contact Us
• Disclaimer
• Source